PolTREG (PTG.WA)

Executive Summary

PolTREG S.A. is a Polish biotechnology company pioneering T-regulatory cell (Treg) therapies for autoimmune diseases. Its lead candidate, PTG007, is designed to restore immune tolerance and potentially modify the course of Type 1 Diabetes (T1D) and Multiple Sclerosis (MS). Built on over 17 years of research, the company operates its own state-of-the-art manufacturing facility, providing a strategic advantage in cell therapy production. With a strong intellectual property position and a focus on high unmet medical needs, PolTREG is positioned as a promising player in the cell & gene therapy space. The company is publicly traded on the Warsaw Stock Exchange (ticker: PTG.WA) with a current valuation of approximately $79 million. While still in early clinical stages, PolTREG's approach addresses the root cause of autoimmunity, offering potential for disease modification rather than symptom management. Key upcoming milestones include initial clinical data readouts and regulatory progress, which could serve as near-term catalysts.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 data readout for PTG007 in Type 1 Diabetes60% success
• Q2 2026FDA IND clearance for PTG007 in Multiple Sclerosis70% success
• Q3 2026Strategic partnership or non-dilutive grant for manufacturing expansion40% success